Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma

A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02301208

Acronym

NPC-RCT-WCRT

Enrollment

120

Registered

2014-11-25

Start date

2014-12-31

Completion date

Unknown

Last updated

2014-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).

Interventions

DRUGNedaplatin

Nedaplatin combine with IMRT

DRUGCisplatin

Cisplatin combine with IMRT

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Pathologically confirmed untreated NPC patients * T1-2N1-3M0 or T3-4NxM0 * 18-70 years old * with MRI examinations * ECOG ≤ 2 * With written consent

Exclusion criteria

* With a second cancer * Pregnancy * With other severe diseases (blood,liver ,kidney or heart diseases) * Could not be staged properly * Without written consent

Design outcomes

Primary

Measure	Time frame
Response rate	2 years
Progress-free survival	2 years

Secondary

Measure	Time frame
Tumor response	radiotherapy in 2 week、4 week、7 week
Overall survival	2 years

Contacts

Primary ContactLi Yin, M.D. Ph.D.

yinli7878@sina.com+8613913909043

Backup ContactPengwei Yan, M.M.

179032794@qq.com+8613815888775

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026